glp-1 drugs thyroid cancer agonist like Ozempic do not increase risk Increased screening may lead to
Description
FDA-approved for chronic weight management
Patients with eating disorders, extreme frailty or very low BMI may experience more harm than benefit
Soon, liraglutide was approved for both T2DM (Victoza, Novo Nordisk, Denmark) and obesity under the name of Saxenda (Novo Nordisk) for once-daily use [18,20]
However, these experiences are common and multifactorial, influenced by dietary composition, stress, sleep quality, physical activity, and numerous other hormonal systems beyond GLP-1
